Form 8-K - Current report:
SEC Accession No. 0001437749-25-000796
Filing Date
2025-01-10
Accepted
2025-01-10 07:03:13
Documents
16
Period of Report
2025-01-03
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.01: Completion of Acquisition or Disposition of Assets
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nby20250107_8k.htm   iXBRL 8-K 36354
2 EXHIBIT 2.1 ex_762783.htm EX-2.1 51211
3 EXHIBIT 10.1 ex_762784.htm EX-10.1 23530
  Complete submission text file 0001437749-25-000796.txt   267732

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA nby-20250103.xsd EX-101.SCH 3400
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nby-20250103_def.xml EX-101.DEF 11803
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE nby-20250103_lab.xml EX-101.LAB 15857
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nby-20250103_pre.xml EX-101.PRE 12018
18 EXTRACTED XBRL INSTANCE DOCUMENT nby20250107_8k_htm.xml XML 2950
Mailing Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608
Business Address 2000 POWELL STREET, SUITE 1150 EMERYVILLE CA 94608 (510) 899-8800
NovaBay Pharmaceuticals, Inc. (Filer) CIK: 0001389545 (see all company filings)

EIN.: 680454536 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33678 | Film No.: 25520351
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)